September 26, 2016 3:53 AM ET


Company Overview of Protein Sciences Corporation

Company Overview

Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...

1000 Research Parkway

Meriden, CT 06450

United States

Founded in 1983





Key Executives for Protein Sciences Corporation

Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Chief Medical Officer
Senior Vice President of Quality
Compensation as of Fiscal Year 2016.

Protein Sciences Corporation Key Developments

Protein Sciences Corporation and Avanzcare Sign Exclusive Agreement for Distribution of Flublok® and Panblok® Influenza Vaccines to Middle East and North Africa

Protein Sciences Corporation and Avanzcare announced that they have signed an agreement designating Avanzcare as the exclusive distributor of Protein Sciences Corporation's proprietary Flublok® (seasonal) and Panblok® influenza vaccines and potentially other vaccines to be developed in the future for certain Middle East and North Africa markets. Under the terms of the agreement, Avanzcare will pursue registration of Flublok in all licensed countries and will initially purchase Flublok from Protein Sciences for distribution in the region. The MENA region represents about 6% of the total world population. This agreement dramatically expands the global footprint of Flublok and other Protein Sciences' vaccines.

Sinergium Biotech and Protein Sciences Corporation to Produce Zika Vaccine by 2018

Protein Sciences Corporation, Sinergium Biotech, and Mundo Sano, a private foundation with activities in Argentina, Spain, and Africa, have announced that their clinical testing of candidate Zika vaccines is progressing well and forecast that by 2018 they will have a Zika vaccine ready to launch in the market. The vaccine being developed is based on production of recombinant variations of the E protein from the Zika virus. Similar vaccine candidates produced at Protein Sciences against West Nile virus and Japanese encephalitis virus, which are close relatives of the Zika virus, have previously been shown to neutralise their respective targets in preclinical studies. The companies have focused on active discussions with additional strategic partners worldwide that could strengthen and rapidly advance the development programme.

Protein Sciences Corporation Announces Release of First Lots of Flublok® Influenza Vaccine

Protein Sciences Corporation announced that the FDA has approved and released the first lots of Flublok® influenza vaccine for distribution this season. Doses have been shipped and healthcare professionals and pharmacies that have pre-ordered Flublok should receive the vaccine this week. Flublok is approved for all people 18 and older and was recently shown in a clinical study of adults 50 and older to provide over 40% better protection against cell culture confirmed influenza compared to a flu vaccine made using embryonated hens' eggs the 60 – year old vaccine production technology. Flublok also offers a pure choice for vaccination as it is comprised of purified protein and lacks the unnecessary ingredients contained in other flu vaccines, such as influenza virus, antibiotics, preservatives, egg protein, gelatin or latex.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Protein Sciences Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at